Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Basilea Pharmaceutica ( (CH:BSLN) ) is now available.
Basilea Pharmaceutica announced that the US Biomedical Advanced Research and Development Authority (BARDA) has approved an additional $25 million funding for the development of its antifungal agents, Fosmanogepix and BAL2062. This funding supports ongoing Phase 3 studies and could significantly impact the company’s operations by advancing its drug development pipeline, potentially enhancing its market position in the treatment of life-threatening fungal infections.
The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF69.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.
More about Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company focused on developing and marketing innovative drugs for severe bacterial and fungal infections. It has successfully launched hospital-use drugs like Cresemba for invasive fungal infections and Zevtera for bacterial infections. The company is listed on the Swiss stock exchange.
Average Trading Volume: 42,598
Technical Sentiment Signal: Buy
Current Market Cap: CHF565.8M
For detailed information about BSLN stock, go to TipRanks’ Stock Analysis page.